Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Ambien Line Extension Planned For 2004; Still Confident In Arixtra   

Executive Summary

Sanofi-Synthelabo plans to file for approval of a modified-release formulation of the insomnia agent Ambien during the second quarter of 2004

You may also be interested in...



Sanofi-Aventis Pipeline Includes Sleep Quality Aid, Depression Therapy

Positive early clinical results for Sanofi-Aventis' sleep disorder therapy eplivanserin could lead to the development of a "new concept" for improving quality of sleep, Senior Exec VP-Science & Medical Affairs Gerard Le Fur said

Sanofi-Aventis Pipeline Includes Sleep Quality Aid, Depression Therapy

Positive early clinical results for Sanofi-Aventis' sleep disorder therapy eplivanserin could lead to the development of a "new concept" for improving quality of sleep, Senior Exec VP-Science & Medical Affairs Gerard Le Fur said

Novartis Misses Out On Another Merger, But Forces Sanofi To Pay More

Novartis will need to start over in its search for a merger partner after bowing out of the bidding process for Aventis

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel